Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1

Diego Piqueras-Losilla, Andrea Garcia-Rey, Aline Huguet-Lachon, Argimiro Mayoral-Olmos, Isabel Campillo, Melanie Nufer, Mouli Chakraborty, Ana Díaz-Maqueda, Nuria Barquero, Anchel Gonzalez-Barriga, José Martinez-Hernandez, María Gracia de Garnica García, Geneviève Gourdon, Ruben Artero, Beatriz Llamusí, Estefanía Cerro-Herreros

Open source

DOI: 10.1016/j.xcrm.2026.102929
Published: 2026-08
Container: Cell Reports Medicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.xcrm.2026.102929,
  title = {Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1},
  author = {Diego Piqueras-Losilla and Andrea Garcia-Rey and Aline Huguet-Lachon and Argimiro Mayoral-Olmos and Isabel Campillo and Melanie Nufer and Mouli Chakraborty and Ana Díaz-Maqueda and Nuria Barquero and Anchel Gonzalez-Barriga and José Martinez-Hernandez and María Gracia de Garnica García and Geneviève Gourdon and Ruben Artero and Beatriz Llamusí and Estefanía Cerro-Herreros},
  year = {2026},
  journal = {Cell Reports Medicine},
  doi = {10.1016/j.xcrm.2026.102929},
  url = {https://doi.org/10.1016/j.xcrm.2026.102929}
}

RIS

TY  - JOUR
TI  - Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1
AU  - Diego Piqueras-Losilla
AU  - Andrea Garcia-Rey
AU  - Aline Huguet-Lachon
AU  - Argimiro Mayoral-Olmos
AU  - Isabel Campillo
AU  - Melanie Nufer
AU  - Mouli Chakraborty
AU  - Ana Díaz-Maqueda
AU  - Nuria Barquero
AU  - Anchel Gonzalez-Barriga
AU  - José Martinez-Hernandez
AU  - María Gracia de Garnica García
AU  - Geneviève Gourdon
AU  - Ruben Artero
AU  - Beatriz Llamusí
AU  - Estefanía Cerro-Herreros
PY  - 2026
JO  - Cell Reports Medicine
DO  - 10.1016/j.xcrm.2026.102929
UR  - https://doi.org/10.1016/j.xcrm.2026.102929
ER  -

APA

Piqueras-Losilla, D., Garcia-Rey, A., Huguet-Lachon, A., Mayoral-Olmos, A., Campillo, I., Nufer, M., Chakraborty, M., Díaz-Maqueda, A., Barquero, N., Gonzalez-Barriga, A., Martinez-Hernandez, J., García, M. G. D. G., Gourdon, G., Artero, R., Llamusí, B., & Cerro-Herreros, E. (2026). Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1. Cell Reports Medicine. https://doi.org/10.1016/j.xcrm.2026.102929

Source records

crossref · retrieved 2026-09-25T14:25:39.120Z